Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
22.86
+0.32 (+1.42%)
Delayed Quote
Updated: 9:48 AM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
November 04, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
October 27, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
October 15, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
October 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short
↗
May 12, 2026
Via
Chartmill
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
September 25, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
September 15, 2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
September 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
↗
August 31, 2026
One of J&J's investments stands head-and-shoulders above the rest.
Via
The Motley Fool
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
CARVYKTI sales surged 50% globally as company swung to profitability.
Via
The Motley Fool
Topics
Earnings
Legend Biotech Q2 Earnings Call Highlights
↗
August 11, 2026
Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and...
Via
MarketBeat
Topics
Earnings
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces CEO Transition
July 27, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
↗
June 27, 2026
It has been a banner year for biotech buyouts, and these are two of the prime targets.
Via
The Motley Fool
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Keep an eye on the top gainers and losers in Tuesday's session.
↗
June 02, 2026
Via
Chartmill
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 02, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use
↗
May 31, 2026
Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for...
Via
MarketBeat
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
↗
May 17, 2026
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Via
The Motley Fool
Topics
Regulatory Compliance
With YMM Down 29%, First Beijing Bought 13 Million More Shares
↗
May 17, 2026
Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
Via
The Motley Fool
Topics
Regulatory Compliance
Legend Biotech (LEGN) Q1 2026 Earnings Transcript
↗
May 12, 2026
Legend Biotech (LEGN) Q1 2026 Earnings Transcript
Via
The Motley Fool
Legend Biotech Q1 Earnings Call Highlights
↗
May 12, 2026
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of...
Via
MarketBeat
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
